Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism - PubMed (original) (raw)
Angiotensin II increases glucose utilization during acute hyperinsulinemia via a hemodynamic mechanism
T A Buchanan et al. J Clin Invest. 1993 Aug.
Abstract
To determine whether hemodynamic changes can modulate insulin action in vivo, we administered angiotensin II (AII) to normal men under three separate, euglycemic conditions. First, in the presence of physiological hyperinsulinemia (approximately 115 microU/ml), infusion of AII at rates of 2, 10, and 20 ng/min per kg caused significant elevations of blood pressure, whole-body glucose clearance, and plasma insulin concentrations in an AII dose-dependent manner. Second, in the presence of plasma insulin concentrations that stimulate glucose transport maximally (approximately 5,000 microU/ml), AII infusions increased whole-body glucose clearance without enhancing glucose extraction across the leg. Third, in the presence of basal insulin concentrations (approximately 13 microU/ml), AII infusions had no effect on whole-body glucose turnover or leg glucose extraction. Thus, AII enhanced whole-body glucose utilization without directly stimulating glucose transport in a major skeletal muscle bed. To evaluate a possible hemodynamic mechanism for the effects of AII on glucose utilization, we measured blood flow to two areas that differ in their sensitivity to insulin: the kidneys and the leg. We found that AII redistributed blood flow away from the predominantly insulin-independent tissues of the kidney and toward the insulin-sensitive tissues of the leg during both sham and hyperinsulinemic glucose clamps. The redistribution of flow had no effect on whole-body glucose turnover when leg glucose uptake was unstimulated (sham clamps). However, when leg glucose uptake was activated by insulin, the redistribution of flow caused a net increase in whole-body glucose utilization. Our findings indicate that hemodynamic factors can modulate insulin action in vivo. Furthermore, our results suggest that variable activity of the renin-angiotensin system may contribute to inconsistencies in the association between insulin resistance and hypertension.
Similar articles
- Alterations in angiotensin II release and vascular reactivity in hypertensive men: a pilot study.
Gasic S, Ratheiser K, Wagner O, Nowotny P, Vierhapper H, Waldhäusl W. Gasic S, et al. Am J Hypertens. 1999 Nov;12(11 Pt 1):1055-62. doi: 10.1016/s0895-7061(99)00137-5. Am J Hypertens. 1999. PMID: 10604480 Clinical Trial. - Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling.
Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M, Shojima N, Ono H, Onishi Y, Fujishiro M, Katagiri H, Fukushima Y, Kikuchi M, Noguchi N, Aburatani H, Komuro I, Fujita T. Ogihara T, et al. Hypertension. 2002 Dec;40(6):872-9. doi: 10.1161/01.hyp.0000040262.48405.a8. Hypertension. 2002. PMID: 12468572 - Training-induced enhancement of insulin action in human skeletal muscle: the influence of aging.
Dela F, Mikines KJ, Larsen JJ, Galbo H. Dela F, et al. J Gerontol A Biol Sci Med Sci. 1996 Jul;51(4):B247-52. doi: 10.1093/gerona/51a.4.b247. J Gerontol A Biol Sci Med Sci. 1996. PMID: 8680988 - Angiotensin II induces insulin resistance independent of changes in interstitial insulin.
Richey JM, Ader M, Moore D, Bergman RN. Richey JM, et al. Am J Physiol. 1999 Nov;277(5):E920-6. doi: 10.1152/ajpendo.1999.277.5.E920. Am J Physiol. 1999. PMID: 10567021 - A dynamic model of angiotensin II infusion experiments.
White KP Jr, Radke-Sharpe NF, Kaiser DL, Owens GK. White KP Jr, et al. J Biomed Eng. 1989 Jan;11(1):63-71. doi: 10.1016/0141-5425(89)90168-4. J Biomed Eng. 1989. PMID: 2648070 Review.
Cited by
- The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome.
Putnam K, Shoemaker R, Yiannikouris F, Cassis LA. Putnam K, et al. Am J Physiol Heart Circ Physiol. 2012 Mar 15;302(6):H1219-30. doi: 10.1152/ajpheart.00796.2011. Epub 2012 Jan 6. Am J Physiol Heart Circ Physiol. 2012. PMID: 22227126 Free PMC article. Review. - Methodological aspects, dose-response characteristics and causes of interindividual variation in insulin stimulation of limb blood flow in normal subjects.
Utriainen T, Malmström R, Mäkimattila S, Yki-Järvinen H. Utriainen T, et al. Diabetologia. 1995 May;38(5):555-64. doi: 10.1007/BF00400724. Diabetologia. 1995. PMID: 7489838 - Angiotensin and insulin resistance: conspiracy theory.
Townsend RR. Townsend RR. Curr Hypertens Rep. 2003 Apr;5(2):110-6. doi: 10.1007/s11906-003-0066-1. Curr Hypertens Rep. 2003. PMID: 12642009 Review. - Angiotensin II type 1 and type 2 receptors regulate basal skeletal muscle microvascular volume and glucose use.
Chai W, Wang W, Liu J, Barrett EJ, Carey RM, Cao W, Liu Z. Chai W, et al. Hypertension. 2010 Feb;55(2):523-30. doi: 10.1161/HYPERTENSIONAHA.109.145409. Epub 2009 Dec 7. Hypertension. 2010. PMID: 19996061 Free PMC article. - Angiotensin II receptors modulate muscle microvascular and metabolic responses to insulin in vivo.
Chai W, Wang W, Dong Z, Cao W, Liu Z. Chai W, et al. Diabetes. 2011 Nov;60(11):2939-46. doi: 10.2337/db10-1691. Epub 2011 Sep 6. Diabetes. 2011. PMID: 21896931 Free PMC article.
References
- J Clin Endocrinol Metab. 1965 Oct;25(10):1375-84 - PubMed
- Naunyn Schmiedebergs Arch Pharmacol. 1990 Oct;342(4):436-40 - PubMed
- Acta Med Scand. 1976;200(3):163-9 - PubMed
- J Clin Invest. 1980 Jun;65(6):1272-84 - PubMed
- Diabetes. 1981 Mar;30(3):219-25 - PubMed